Predicting early rebleeding and mortality after endoscopic hemostasis of esophagogastric varices: Diagnostic performance of aspartate aminotransferase‐to‐platelet ratio index and model for end‐stage liver disease‐Na score
Journal of Hepato-Biliary-Pancreatic Sciences · 2024
DOI: 10.1002/jhbp.12057 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepato-Biliary-Pancreatic Sciences, 2024. Verfasst von Shinya Yokoyama und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan. Hauptthemen laut MEDLINE: Esophageal and Gastric Varices, Gastrointestinal Hemorrhage, Recurrence, Hemostasis, Endoscopic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background
Endoscopic variceal ligation and sclerotherapy are recommended for esophagogastric variceal bleeding (EGVB) in cirrhosis but can be complicated by early rebleeding and death. This study aimed to identify noninvasive markers accurately predicting early rebleeding and mortality after endoscopic hemostasis for EGVB.
Methods
Among 116 patients with endoscopically confirmed EGVB and endoscopic hemostasis, various noninvasive markers were calculated, and their predictive accuracy was compared by receiver‐operating characteristic curve analysis. Endpoints included 5‐day rebleeding, 5‐day mortality, 6‐week rebleeding, and 6‐week mortality.
Results
The median age was 63 years. Child‐Pugh class B and C patients accounted for 40.5% and 34.5%, respectively. Only the aspartate aminotransferase‐to‐platelet ratio index (APRI) significantly predicted 5‐day rebleeding, with an area under the curve (AUC) of 0.777 (95% confidence interval [CI]: 0.537–1). The model for end‐stage liver disease‐Na (MELD‐Na) score showed good predictive accuracy for 5‐day mortality (AUC: 0.839, 95% CI: 0.681–0.997), 6‐week rebleeding (AUC: 0.797, 95% CI: 0.663–0.932), and 6‐week mortality (AUC: 0.888, 95% CI: 0.797–0.979).
Conclusions
Patients with cirrhosis with a high APRI and MELD‐Na score were at high risk of early rebleeding and death after EGVB. Allocating appropriate monitoring and care for those patients is necessary.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
ORCID-Profile: Shinya Yokoyama, Hiroki Kawashima
Zitieren
APA
Yokoyama, S., Honda, T., Ishizu, Y., Imai, N., Ito, T., Yamamoto, K., Mizuno, K., Nakamura, M., & Kawashima, H. (2024). Predicting early rebleeding and mortality after endoscopic hemostasis of esophagogastric varices: Diagnostic performance of aspartate aminotransferase‐to‐platelet ratio index and model for end‐stage liver disease‐Na score. Journal of Hepato-Biliary-Pancreatic Sciences. https://doi.org/10.1002/jhbp.12057
Vancouver
Yokoyama S, Honda T, Ishizu Y, Imai N, Ito T, Yamamoto K, et al. Predicting early rebleeding and mortality after endoscopic hemostasis of esophagogastric varices: Diagnostic performance of aspartate aminotransferase‐to‐platelet ratio index and model for end‐stage liver disease‐Na score. Journal of Hepato-Biliary-Pancreatic Sciences. 2024. doi:10.1002/jhbp.12057
BibTeX
@article{Yokoyama2024,
author = {Yokoyama, Shinya and Honda, Takashi and Ishizu, Yoji and Imai, Norihiro and Ito, Takanori and Yamamoto, Kenta and Mizuno, Kazuyuki and Nakamura, Masanao and Kawashima, Hiroki},
title = {Predicting early rebleeding and mortality after endoscopic hemostasis of esophagogastric varices: Diagnostic performance of aspartate aminotransferase‐to‐platelet ratio index and model for end‐stage liver disease‐Na score},
journal = {Journal of Hepato-Biliary-Pancreatic Sciences},
year = {2024},
doi = {10.1002/jhbp.12057}
}
EUVIMED